Patient characteristics and baseline values of PD15FEV1, FEV1, daily PEF, symptom scores, and use of rescue medication in the two treatment groups
| Fluticasone propionate (n=13) | Placebo (n=13) | |
|---|---|---|
| Continuous variables are expressed as mean (range) values. | ||
| *Geometric mean. | ||
| **Reference values: Nunn and Gregg.20 | ||
| ***Reference values: Viljanen et al.14 | ||
| †p<0.02 (comparison between treatment groups). | ||
| Height (cm) | 169 (157–189) | 174 (160–194) |
| Weight (kg) | 67.3 (45–88) | 78.4 (48–113) |
| Age (years) | 34.5 (21–53) | 38.5 (21–59) |
| M/F | 4/9 | 7/6 |
| Smoking (never/ex–smokers) | 9/4 | 9/4 |
| Mean duration of reversible airway obstruction (years) | 12.9 (0.1–37) | 8.0 (0.1–33) |
| No of atopics | 9 | 10 |
| FEV1 (% pred)*** | 79.3 (70–88) | 84.3 (69–100) |
| PD15FEV1 (mg)* | 0.122 (0.016–0.498) | 0.233 (0.006–1.10) |
| Mean daily PEF (% pred)** | ||
| Morning | 81 (64–99) | 92 (71–112)† |
| Evening | 83 (63–99) | 95 (72–116)† |
| Mean symptom score | ||
| Daytime (0–5) | 0.12 | 0.27 |
| Night time (0–4) | 0.46 | 0.51 |
| Mean weekly sum of doses of rescue medication | 3.8 | 4.6 |